GSK1292263
99%
- Product Code: 62641
CAS:
1032823-75-8
| Molecular Weight: | 456.56 g./mol | Molecular Formula: | C₂₃H₂₈N₄O₄S |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD18385004 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
GSK1292263 is primarily investigated for its potential therapeutic applications in the treatment of metabolic disorders, particularly type 2 diabetes. It functions as a GPR119 agonist, targeting the G-protein-coupled receptor 119, which plays a role in glucose homeostasis and insulin secretion. By activating this receptor, it enhances the release of incretin hormones like GLP-1, thereby improving glucose-dependent insulin secretion and potentially aiding in blood sugar regulation. Its application is focused on developing oral medications that can effectively manage diabetes with fewer side effects compared to existing therapies. Research is ongoing to evaluate its efficacy, safety, and potential as a long-term treatment option for diabetic patients.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White to Off-white to Light yellow to Light brown Solid |
| PURITY | 98.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | £139.84 |
+
-
|
| 0.025 | 10-20 days | £365.78 |
+
-
|
GSK1292263
GSK1292263 is primarily investigated for its potential therapeutic applications in the treatment of metabolic disorders, particularly type 2 diabetes. It functions as a GPR119 agonist, targeting the G-protein-coupled receptor 119, which plays a role in glucose homeostasis and insulin secretion. By activating this receptor, it enhances the release of incretin hormones like GLP-1, thereby improving glucose-dependent insulin secretion and potentially aiding in blood sugar regulation. Its application is focused on developing oral medications that can effectively manage diabetes with fewer side effects compared to existing therapies. Research is ongoing to evaluate its efficacy, safety, and potential as a long-term treatment option for diabetic patients.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
£0.00
£0.00
Total :